Sacituzumab tirumotecan (sac-TMT)
Phase 3 TroFuse-005 met its OS and PFS endpoints in endometrial cancer in Q2 2026.
What it is
Antibody-drug conjugate in late-stage trials across several solid tumors. TroFuse-005 is a Phase 3 study in advanced or recurrent endometrial cancer.
Why it matters to the stock. Sac-TMT is one of the company's main oncology bets to follow Keytruda, and it needs more Phase 3 success to matter to revenue.
News
Sac-TMT Phase 3 TroFuse-005 meets overall and progression-free survival endpoints in endometrial cancer
Merck said its Phase 3 TroFuse-005 trial of sacituzumab tirumotecan (sac-TMT) met both primary endpoints, overall survival and progression-free survival, versus physician's choice chemotherapy in advanced or recurrent endometrial cancer patients who had already received platinum chemotherapy and anti-PD-1 or anti-PD-L1 therapy.
Project